Skip to main content

Peer Review reports

From: Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Original Submission
9 Jan 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Jul 2023 Reviewed Reviewer Report - Jasvinder Singh
16 Jul 2023 Reviewed Reviewer Report
4 Aug 2023 Author responded Author comments - Srikala S. Sridhar
Resubmission - Version 3
4 Aug 2023 Submitted Manuscript version 3
15 Aug 2023 Author responded Author comments - Srikala S. Sridhar
Resubmission - Version 4
15 Aug 2023 Submitted Manuscript version 4
18 Aug 2023 Author responded Author comments - Srikala S. Sridhar
Resubmission - Version 5
18 Aug 2023 Submitted Manuscript version 5
21 Aug 2023 Reviewed Reviewer Report
31 Aug 2023 Reviewed Reviewer Report - Jasvinder Singh
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
5 Sep 2023 Editorially accepted
29 Sep 2023 Article published 10.1186/s12885-023-11380-6

You can find further information about peer review here.

Back to article page